Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Graphite Bio's share price for the quarter that ended in Dec. 2023 was $18.34. Graphite Bio's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 58.01 Mil. Therefore, Graphite Bio's market cap for the quarter that ended in Dec. 2023 was $1,063.87 Mil.
Graphite Bio's quarterly market cap
declined
from Jun. 2023 ($1,055.41 Mil) to Sep. 2023 ($1,006.39 Mil) but then
increased
from Sep. 2023 ($1,006.39 Mil) to Dec. 2023 ($1,063.87 Mil).
Graphite Bio's annual market cap
declined
from Dec. 2021 ($5,047.52 Mil) to Dec. 2022 ($1,353.07 Mil) and
declined
from Dec. 2022 ($1,353.07 Mil) to Dec. 2023 ($1,063.87 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Graphite Bio's Enterprise Value for Today is $1,112.46 Mil.
Graphite Bio Market Cap Historical Data
The historical data trend for Graphite Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Graphite Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Graphite Bio Market Cap Distribution
For the Biotechnology industry and Healthcare sector, Graphite Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Graphite Bio's Market Cap falls into.
Graphite Bio Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Graphite Bio's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Graphite Bio (NAS:GRPH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Graphite Bio Market Cap Related Terms
Thank you for viewing the detailed overview of Graphite Bio's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRPH has been successfully added to your 